Purpose: This study was designed to investigate the use of a prostatic androgen-dependent promoter to mediate antisense targeting of ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC) and its effects on the synthesis of polyamine. We also examined the potential of this construct for prostate cancer therapy.
Methods: pADxsi-PSES-AdoMetDC-ODC-PolyA AV was constructed and used to infect various cancer cell lines, including LNCaP, HT-29, H1299, HepG2. The effects of pADxsi-PSES-AdoMetDC-ODC-PolyA AV on the expression of ODC and AdoMetDC, in addition to the cell cycle, apoptosis and p21 levels, were analyzed through Western blotting and cytometry. A Matrigel invasion assay was used to analyze the effects of the recombinant virus on tumor cell invasion. The effect on polyamine content was also determined, and the relationship between inhibition of cellular ODC and AdoMetDC and decreases in polyamine were also investigated using a polyamine recovery assay.
Results: Treatment with pADxsi-PSES-AdoMetDC-ODC-PolyA at an MOI of 90 significantly inhibited the proliferation of LNCaP cells, which could not be recovered through the addition of exogenous putrescine. The expression of ODC and AdoMetDC was also reduced, as was the polyamine content. The G1 phase of LNCaP cells was delayed, but no increase in apoptosis was detected. The down-regulation of ODC and AdoMetDC led to increased p21 expression.
Conclusions: The pADxsi-PSES-AdoMetDC-ODC-PolyA AV specifically inhibited the expression of ODC and AdoMetDC and the synthesis of polyamine, while it induced p21 expression, resulting in cell growth arrest in the G1 phase in prostate cancer cells but not in other cells.
(c) 2008 Wiley-Liss, Inc.